# Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

> **NCT07691970** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 1072 (estimated)

## Conditions studied

- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

## Interventions

- **COMBINATION_PRODUCT:** Anifrolumab
- **COMBINATION_PRODUCT:** Anifrolumab
- **DRUG:** Anifrolumab

## Key facts

- **NCT ID:** NCT07691970
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2032-12-30
- **Final completion:** 2032-12-30
- **Target enrollment:** 1072 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691970, "Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*